The sound of getting rid of coronavirus by RNA interference technology: RNAi against COVID-19

No Abstract.

A light shining through darkness: probiotic against COVID-19

No Abstract

Evaluation of the effect of vaccination on transmissibility and pathogenicity of Omicron variant and its comparison with other SARS-CoV-2 variants

The new variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has once again sounded the alarm on healthcare systems worldwide and has caused concern in some countries. This variant has been identified in South Africa and initially called B.1.1.529 and later renamed Omicron by the WHO. The transmissibility and immune evasion in the Omicron variant (B.1.1.529) is higher than the previous variants. Compared to the previous dominant variant, which was called the Delta variant, the Omicron variant has a very high transmission power but luckily, Omicron's symptoms are less serious. According to the WHO, the Omicron variant has the potential to re-infect people who already have other variants of SARS-CoV-2. Omicron contains at least 32 mutations in the spike protein also other proteins that are required for viral replication and it is twice the size of delta variant. Half of the mutations in this variant occur in the area of the virus through which they bind to the cells of the human body and cause infection. The Omicron variant likely developed in one person during chronic infection with an immune system deficiency (possibly untreated HIV/AIDS). It is possible that injecting a booster dose of existing vaccines and subsequently increasing antibody levels will provide adequate protection and an appropriate barrier against Omicron. The purpose of this article is to evaluate the Omicron variant and compare it with other SARS-CoV-2 variants and the effect of a booster dose in preventing disease progression

A mini‑review of the validity, quality and efficacy of candidate vaccines in controlling the COVID-19

Few would have thought that in this century, a new coronavirus called SARS-CoV-2 would kill many people around the world, cripple the economy, and leave the medical staff helpless. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a virus that first appeared in Wuhan, China, and spread rapidly around the world, and strict quarantines did not prevent the severe prevalence from spreading worldwide. Antiviral drugs do not work well enough for everyone. The mortality rate in the world is still significant. The only thing that gives hope to the people of the world is the hope of being vaccinated, so by producing vaccines in the shortest possible time, science has once again saved humanity. Thus, from the very beginning, pharmaceutical companies started to produce safe vaccines. Currently, more than 200 types of vaccines around the world are undergoing various stages of production, and about 30 vaccines have entered the clinical trial phase, of which 9 vaccines have entered phase 1 to 3 of clinical trials. DNA and RNA-based vaccines were first developed and were not licensed before coronavirus disease 2019 (COVID-19). Other types of vaccines, including non-replicating viral vectors as well as inactivated vaccines, are undergoing clinical phases. There are currently 9 common vaccines Inovio Pharmaceuticals, Moderna, BioNTech/Pfizer, AstraZeneca, CanSino Biological, Gam-COVID-Vac (Sputnik V), Wuhan Institute of Biological Products/Sinopharm, Beijing Institute of Biological Products/Sinopharm, and Sinovac Institutes in the world. Vaccination with the Pfizer vaccine, which is approved by the World Health Organization (WHO), is underway in many countries. The WHO predicts that by the end of 2021, one billion people worldwide will be vaccinated by the company